Rick Simpson Oil (RSO) Dillingham Census Area-mi: OilWell Cannabis-aa Nalliiniq Aparriqsitaq

Alaska-a Bristol Bay-aamun ayuqucirtuulqigtun, labamun ayuqertaallranun, paivgarluni

RICK SIMPSON AATENKAAN CALINGARTA RICK SIMPSON OIL

Kina Rick Simpson-a

Rick Simpson-aaq 1949-aami Amherst, Nova Scotia, Canada-aami suaqellruuq. Angutnguallermiunguq, angalkuqungraan kiirullermiunguallermiungraan. Power engineer-aqungraan, maintenance worker-aqungraan caliaqarraallruniluni — blue-collar tradesman-aqungraan, cannabis-aq pillluku calingartellrani imna suallmi patulaluni, yuut nallunrilkiurcecuitellini. Dillingham Census Area-mi una qanemciq aturluku, anermuunani Anchorage-mun oncologist-aq tekicarpegnani plane-rmun pilartuq, au͡gna piviankut qanruyuteteng aturpek’nacuitelliniluki, tua-i tamarmeng yuut nallunrilkiurcecuitelluki. Unangkut tamarmeng nalluyagutaarput imna medical system-m qanrutekluku qimugtellratnek.

1997-aami, Moncton, New Brunswick-aami hospital-aami caliaqellrani scaffolding-aanrani qacugarrluni, qilaakun tamalkuan tukaitellmi tukniluni. Qacuutesqenrilnguut maa-i pillruyaaqaat: tinnitus, dizziness, post-concussion symptoms-aaq tamarmeng modern medicine-aq nallunrilkiurceciquq umyugaqenrilnguq. Simpson-aq qanrulluku, doctor-aat pills-at aturluku nallunrilkiurceciququngraan, cannabis-aq ayuqucimaluni pinirraarluku. Cannabis-aqa doctor-aamini prescription-aaq nallumaluku, imna doctor-aq qanrutkelrianek imna imumi qessaluku. Dillingham Census Area-mi yuut Anchorage-mun specialist-aamun tekicarpek’nani prescriptions-at atullrunrilnguut pills-at atullrunrilnguut pillraarciqalartut — wall’uq imna suffering-rraarciqallranek wall’uq side effects-at pillraarciqallranek iqluluku assiicuaqerpek’nani pillraarciqateng, una ayuqenrilnguq qanemcikput iqluku pikput.

Simpson-aam cannabis-oil-aaq pillluku nalluyagutaaqaqaan 1974-aamun National Institute of Health-aam fund-aaqelallrani Medical College of Virginia-aami cariyanek, imarni THC-aq cancer cell-ait mouse-atgun qanemcimaluni. Una cariyaaq, alerqutekciquq imna niicugnirragni — tuarpak Simpson-aam calingarteng cariyararkaulluku allrakungqerrluni, nallunailkutekluku. Allaqungqertuq Dillingham Census Area-mi research-aam nallunailkutnek, our communities health studies-aurraarciqaput, promising findings-rraarciqaput proven treatments-rraarciqaput.

2003-aami, Simpson-aq qanrulluku, qaingani three bumps doctor-aamun diagnosis-aaqellrani basal cell carcinoma-aq. Modern treatment-aaq pilluku wall’uq concentrated cannabis oil-aq directly bumps-atgun apply-arraarluni, banadigaaqarluni, naulluuqenrilnguq. Una allami naulluuqenrilnguq four days-ami qanemcimaluni. Independent medical verification-aaq publish-aartairulluni, biopsy-aaq wall’uq clinical follow-up-aaq peer-reviewed source-aam qanertairulluni. Una personal experience-aqa Rick Simpson Oil-aam origin story-aquniluni, tamarmeng qanertelartut.

**Ayuqucirtuun: ** Simpson-aam qanemciq imna personal testimonial-aq aturluku. Clinical documentation-aaq, controlled observation-aaq, independent medical confirmation-aaq nalluyagutaartairullini, unateng medical evidence-aq nallunrilkesciigatut. Ilait atutlerkaungraata, nalluyagutaartairullini tamarmeng catalyst-aquniluni global movement-aamun. Dillingham Census Area-mi word-of-mouth, personal experience-rraarciqaput nalluyagutaartairullini health decisions-aaq, testimony-proof-aq iqluku pikput.

Calingarteng — oil-aq pillluku caliarkait

2003-aamun experience-aamini Simpson-aq committed-raarluni concentrated cannabis oil-aq caliaqerraallruniluni. Maccan, Nova Scotia-aami property-aani oil-aq caliaqaquq, cancer patients-amun, community-mi yuutamun free-aq atullruniluni. Nothing-aq aturpek’nani. Una account-aani dozens-aq yuutamun help-rraaniluni: cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, ilaitni. Dillingham Census Area-mi community members-amun commercial fishing season-rraarciqaput, subsistence harvesting-rraarciqaput, harsh winters-rraarciqaput mutual aid-rraarciqaput share-resources-rraarciqaput person-aq need-aaput.

Simpson-aam qanemcik 2005 documentary-mun Run From The Cure, Christian Laurette-aq director-aquniluni, global audience-mun tekicararraallruniluni. Una film-aq Simpson-aam claims-atgun qanertelluni, testimonial-atgun patients-aput aturluni, grassroots challenge-aquniluni pharmaceutical-government interests-aamun. Freely online-aamun distributed-aqanlluni, cannabis advocacy film-aquniluni most widely shared-aquniluni. Cannabis communities-mi foundational-aquniluni, Run From The Cure cannabinoids-aq concentrated cannabis oil-aq medicine-aquniluni concept-aq introduction-aqanlluni.

Simpson-aam advocacy-aq Canadian law-aamun direct conflict-aquniluni. Royal Canadian Mounted Police (RCMP) 2005-aami property-aani raid-aqellrani, plants-equipment-aq seizure-aaqellrani. Cannabis cultivation, possession, trafficking-aq charge-aaqellrani. Community support-aq, public attention-aq qaillun pilalliniluni, 2009-aami raid-aqanlluni. Some charges-aq acquitted-aqanlluni, others-aq convicted-aqanlluni. Legal pressure-aq qaillun pilalliniluni, Simpson-aq Canada-aamun ayallruniluni, Europe-aamun relocate-arraallruniluni, Croatia-aamun, Netherlands-aamun living-aqanlluni, advocacy-aq abroad-aamun caliaqerraallruniluni.

2012-aami Simpson-aq Phoenix Tears: The Rick Simpson Story publish-aqanlluni, personal experience-aq, oil-making process-aq, broader philosophical views-aq cannabis, medicine, institutional suppression-aquniluni. phoenixtears.ca-aaq primary online platform-aquniluni information-advocacy-aquniluni.

Simpson-aam public career-aami position-aq consistent-uncompromising-aquniluni: cannabis oil-aq — especially high-THC oil-aq specific method-aquniluni — cancer-aq other diseases-aq cure-aquniluni, pharmaceutical companies, government agencies, medical institutions-aq knowledge-aq suppress-aquniluni financial interests-aq protect-aquniluni. Work-aq health advocacy-aqungraan, institutional corruption-aquniluni fight-aquniluni.

**Ayuqucirtuun: ** Simpson-aam conspiratorial framing-aq note-aqanlluni endorsement-dismissal-rruarciqnganiluni. Early cannabis movement-aami worldview-aq shared-aqaniluni, RSO culturally significant-aquniluni. Dillingham Census Area-mi federal overreach-aq subsistence rights-aq environmental regulations-aq iqluku institutional distrust-aq understood-aqaniluni, evidence medical decisions-aq guide-aqaniluni understood-aqaniluni.

Traditional RSO protocol — Simpson-aam 60-gram, 90-day regimen

Simpson-aam core treatment recommendation-aq structured oral protocol-aquniluni, 60 grams (approximately 60 mL) concentrated cannabis oil-aq roughly 90 days-aamun deliver-aquniluni. Cancer treatment protocol-aquniluni, other conditions-aquniluni recommend-aqellrani. Protocol-aq Simpson-aq describe-aqaniluni detailed breakdown-aquniluni.

Goal

Approximately 90 days-aamun 60 grams concentrated, high-THC cannabis oil-aq consume-rraarluni. Simpson-aq serious cancer treatment course-aquniluni minimum amount-aquniluni.

Titration schedule

• Week 1: Half grain of dry rice-aq size-aq dose-aquniluni — roughly 10 to 15 milligrams oil-aq — three times per day (morning, afternoon, before bed) taken-rraarluni. Total daily intake: approximately 30 to 45 milligrams. Simpson-aq initial doses-aq very small-aquniluni, body-aq psychoactive effects-aq THC-aqut begin adjusting-aquniluni.

• Weeks 2 through 5: Approximately every four days dose-aq double-aquniluni. Slow ramp-up-aq purpose-aq THC tolerance gradually build-aquniluni, psychoactive effects-aq disruption minimize-aquniluni. Escalation period-aq end-aq (roughly four to five weeks) target-aq approximately 1 gram (1,000 milligrams) oil per day, three roughly equal doses-aq divided-aquniluni.

• Weeks 5 through 12: Full dose-aq approximately 1 gram per day, three doses-aq roughly 333 milligrams each-aq divided-aquniluni, continue-aquniluni full 60 grams consume-aqaniluni. Dosing level-aq, remaining 50-plus grams oil-aq final seven to eight weeks-aamun consume-aqaniluni.

Administration methods

• Primary method — oral: Simpson-aq dose-aq directly under tongue-aq (sublingual) place-aquniluni wall’uq swallow-aquniluni. Oral ingestion-aq systemic absorption-aq most important route-aquniluni, internal cancers-other systemic conditions-aq primary method-aquniluni.

• Secondary method — topical: Skin cancers-external lesions-aq, Simpson-aq oil-aq directly affected area-aq apply-aquniluni, bandage-aq cover-aquniluni, bandage-aq every three to four days change-aquniluni. Topical application-aq oral dosing-aq skin cancers-aq combine-aquniluni.

• Not recommended as primary — inhalation: Simpson-aq oil-aq smoke-vaporize-aq primary treatment method-aq recommend-aqanlluni. Inhalation-aq immediate symptom relief-aq (pain, nausea) acknowledge-aquniluni, oral route-aq sustained, high-dose exposure-aq therapeutically essential-aquniluni maintain-aquniluni.

Tolerance and the psychoactive effects

• Simpson-aq patients-aq significant tolerance-aq psychoactive effects-aq THC-aq three to four weeks-aq consistent dosing-aq escalating levels-aq develop-aquniluni.

• Euphoric, sedating, disorienting effects-aq minor-temporary side effect-aquniluni, strongly urged-aquniluni high-aq protocol-aq continue-aqaniluni discourage-aqanlluni.

• Initial doses-aq night-aq before bed-aq take-aquniluni psychoactive effects-aq most intense early titration phase-aq sleep through-aquniluni.

• Patients-aq titration period-aq drive-operate machinery-aq avoid-aq recommended-aqanlluni, family members-aq expect-aqut inform-aquniluni.

Dillingham Census Area-mi commercial fishing jobs-aq long hours-aq, heavy equipment-aq clear-headed operation-aq require-aquniluni, guidance-aq particularly relevant-aquniluni. Community-aq fishing season-aq impairment-aq afford-aqaniluni, family safety-aq paramount-aquniluni.

Post-protocol maintenance

• Full 60-gram course-aq complete-aqaniluni, Simpson-aq maintenance dose-aq approximately 1 to 2 grams oil per month, indefinitely taken-aquniluni recommended-aqanlluni.

• Ongoing low-dose maintenance-aq long-term health-cancer prevention-aq important-aquniluni.

• Maintenance dosing-aq treatment dose-aq much lower-aquniluni, full protocol-aq complete-aqaniluni patients-aq sufficient THC tolerance-aq handle-aq comfortable-aquniluni.

Dietary and lifestyle recommendations

• Simpson-aq oil protocol-aq alongside dietary changes-aq advocate-aqanlluni, sugar intake-aq reducing-aquniluni, processed foods-aq avoiding-aquniluni, overall nutrition-aq improving-aquniluni.

• Dietary protocols-aq oil protocol-aq compared-aq a specific systematic-aqaniluni, dietary advice-aq secondary-general-aquniluni.

Dillingham Census Area-mi residents-aq subsistence lifestyle-aq living-aqaniluni, dietary recommendations-aq traditional foods-aq naturally align-aqaniluni: salmon, berries, moose, wild foods-aqallruniluki generations-aq sustains-aqallruniluki.

Important context for evaluating this protocol

Una protocol-aq one person-aq personal experience-aniluni, anecdotal observations-aq base-aqaniluni design-aqanlluni. Clinical trials-aq, dose-finding studies-aq, pharmacokinetic modeling-aq, formal research process-aq nalluyagutaartairullini. Several critical points-aq apply-aqaniluni:

• No controlled trial validation. Specific 60-gram/90-day protocol-aq any cancer type-any other condition-aq evaluate-aqaniluni published randomized controlled trials, cohort studies, well-documented case series-aq nalluyagutaartairullini.

• Assumes crude, unstandardized material. 60-gram quantity-aq single-strain, THC-dominant extract-aq standardization-aq nalluyagutaartairullini. Traditional RSO-aq actual THC content per gram-aq starting plant material-extraction technique-aq widely varied-aquniluni.

• Very high THC exposure. Peak dosing phase-aq patients-aq roughly 1 gram high-THC oil per day consume-aqaniluni. Traditional RSO-aq 60 to 90 percent THC contain-aqaniluni, approximately 600 to 900 milligrams delta-9 THC per day-aq translates-aquniluni. FDA-approved synthetic THC drug dronabinol-aq typically 2.5 to 20 milligrams per day-aq dosed-aquniluni.

• ** Real risks at these doses.** 600 to 900 milligrams THC daily-aq consume-aqaniluni serious risks-aq carries-aqaniluni: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, cannabis use disorder. These risks-aq GENERAL KNOWLEDGE section-aq well-documented-aqaniluni [1][13][14][15].

• Oncology context. Active cancer-aq patients-aq medically complex-aquniluni. Unregulated, unstandardized cannabis oil-aq primary cancer treatment-aq use-aqaniluni, proven therapies-aq place-aqaniluni, harm-aq introduces-aqaniluni.

Dillingham Census Area-mi oncology specialists-aq access-aq Anchorage-mun expensive travel-aq require-aquniluni, alternatives-aq seek-aqaniluni temptation-aq understandable-aquniluni. Proven cancer treatment-aq delaying-aq irreversible consequences-aq can have-aquniluni. Una protocol-aq conventional oncology care-aq replace-aqaniluni never-aqaniluni.

What is traditional Rick Simpson Oil — the product

Traditional RSO-aq Simpson-aq tukaitellmi concentrated cannabis oil-aq, method-materials-aq define-aqaniluni. Product-aq Simpson-aq produce-aqaniluni as described-aqaniluni.

Source material

Simpson-aq high-THC, indica-dominant cannabis strains-aq used-aqaniluni. Heavy, sedating indica genetics-aq specifically favored-aquniluni, cancer treatment-aquniluni sativa-dominant strains-aq against-aq recommended-aqaniluni, indica strains-aq therapeutic outcomes-aq produce-aquniluni. Own cannabis-aq grow-aquniluni wall’uq trusted growers-aq sourced-aquniluni. Strain standardization-aq nalluyagutaartairullini. Starting material-aq availability-growing season-aq vary-aquniluni.

Dillingham Census Area-mi cannabis cultivation-aq climate-aq limited-aquniluni, indoor growing-aq energy costs-aq significant-aquniluni, variability-aq Nova Scotia-aq even more pronounced-aquniluni.

Extraction solvent

Simpson-aq originally naphtha-aq used-aqaniluni, petroleum-based solvent-aq lighter fluid, Varsol, similar products-aq commercially available-aquniluni. Later 99 percent isopropyl alcohol-aq acceptable alternative-aquniluni endorse-aqanlluni. Butane-acetone-aq, safety-purity concerns-aq other solvents-aq explicitly warned against-aqaniluni. Naphtha-isopropyl alcohol-aq food-grade solvent-aq nalluyagutaartairullini, significant safety issue-aquniluni.

Extraction process

1. Dry-semi-dry cannabis plant material-aq container-aq (typically bucket-aq) place-aqaniluni.
2. Material-aq solvent-aq cover-aquniluni, several minutes-aq agitate-stir-aquniluni, cannabinoids-other fat-soluble compounds-aq plant-aq dissolve-aquniluni.
3. Solvent-aq filter-aq (typically cheesecloth-similar mesh material-aq) pour off-aquniluni, separate collection vessel-aquniluni.
4. Fresh solvent-aq same plant material-aq second time-aq repeat-aquniluni, remaining cannabinoids-aq extract-aquniluni.
5. Combined solvent washes-aq (dark, cannabinoid-rich liquid-aq) rice cooker-similar open-vessel heating device-aq place-aqaniluni.
6. Relatively low heat-aq solvent-aq evaporate-aquniluni. Simpson-aq rice cooker-aq specifically recommended-aquniluni, temperature range-aq solvent evaporate-aquniluni, cannabinoids degrade significantly-aq exceeding point-aquniluni. Temperature-aq still high enough-aq THCa-aq THC-aq decarboxylate-aquniluni, most volatile terpenes-aq destroy-aquniluni.
7. Solvent evaporate-aqaniluni, thick, dark oil-aq vessel-aq bottom-aq remain-aquniluni.
8. Final oil-aq oral syringes-aq transfer-aquniluni, storage-dosing-aquniluni.

Appearance and physical characteristics

Traditional RSO-aq extremely dark — nearly black — thick, viscous, tar-like oil-aquniluni. Strong cannabis odor-aq, solvent-residual smell-aq faint-aq can carry-aquniluni, solvent-aq thoroughly purge-aqaniluni. Consistency-aq sticky, room temperature-aq difficult to handle-aquniluni, slightly warmed-aq more fluid-aquniluni.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. Solvent evaporation-aq heat-aq extract-aq THCa-aq essentially all-aq delta-9 THC-aq convert-aquniluni. Traditional RSO-aq activated, THC-dominant product-aquniluni.
• Naturally occurring minor cannabinoids. Source strain-aq contained-aq CBD, CBN, CBC, CBG, other minor cannabinoids-aq natural ratios-aq present-aquniluni, these-aq controlled-measured-targeted-aq nalluyagutaartairullini.
• No ratio control. Specific cannabinoid ratios-aq adjust-standardize-aq ability-aq nalluyagutaartairullini. Profile-aq entirely source plant-aq genetics-growing conditions-aq determined-aquniluni.
• Estimated THC content. Starting material-aq depend-aq, traditional RSO-aq approximately 60 to 90 percent total THC by weight-aq likely ranged-aquniluni, lab-verified-aq traditional production context-aq nalluyagutaartairullini.

Terpene content

Minimal-none-aquniluni. Solvent extraction-aq (terpenes-aq solvent-aq cannabinoids-aq along-aq dissolve-aquniluni) and subsequent high-heat evaporation process-aq (terpenes-aq cannabinoid degradation thresholds-aq below temperatures-aq volatilize-aquniluni) combination-aq traditional RSO-aq effectively terpene content-aq stripped-aquniluni. Modern formulations-aq deliberately preserve-reintroduce terpenes-aq significant distinction-aquniluni.

Standardization and testing

None-aquniluni. Every batch-aq traditional RSO-aq starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature-duration, individual maker’s process-aq depend-aq different-aquniluni. Simpson-aq cannabis legalization-aq standardized lab-testing infrastructure-aq operate-aq before-aquniluni. Certificate of Analysis-aq, cannabinoid quantification-aq, contaminant screening-aq nalluyagutaartairullini.

Residual solvent risk

Traditional RSO production-aq most significant safety concerns-aquniluni. Naphtha and isopropyl alcohol-aq food-grade solvents-aq nalluyagutaartairullini. Naphtha-aq complex petroleum hydrocarbons mixture-aq benzene, toluene, other toxic-carcinogenic compounds-aq contain-aq may-aquniluni. Incomplete solvent purging-aq (lab testing-aq verify-aq very difficult-aq) finished oil-aq potentially harmful residues-aq leaves-aquniluni.

Modern extraction methods-aq food-grade ethanol-supercritical CO₂-aq specifically use-aquniluni, una problem-aq address-aqaniluni.

Simpson-aam claims-aq evidence record-aquniluni

Rick Simpson-aq oil-aq expansive therapeutic claims-aq make-aqaniluni. RSO-aq cancer-aq cure-aquniluni (including terminal cases-aq) stated-aquniluni, diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, other conditions-aq effective-aquniluni. Claims-aq adamant, consistent, public-aq advocacy career-aq throughout-aquniluni.

Claims-aq actual evidence base-aq evaluate-aqaniluni, same standards-aq document-aq throughout-aq apply-aqaniluni.

What Simpson-aq was not

Simpson-aq scientist, physician, pharmacologist, researcher-aq nalluyagutaartairulluni. Formal training-aq medicine, oncology, pharmacology, clinical research methodology-aq nalluyagutaartairullini. Clinical trial-aq design, conduct, fund, publish-aqaniluni. Results-aq peer review-aq submit-aqaniluni. Entire evidence base-aq personal experience, self-reported patient outcomes, informally gathered testimonials-aq consist-aquniluni — controls-aq, independent verification-aq, imaging confirmation-aq, long-term follow-up-aq, blinding-aq nalluyagutaartairullini.

What preclinical literature-aq shows

Preclinical cannabinoid-cancer literature-aq exist-aquniluni, scientifically interesting-aquniluni:

• In vitro studies-aq THC and CBD-aq apoptosis (programmed cell death) induce-aquniluni, proliferation inhibit-aquniluni, angiogenesis (tumors-aq feed-aq blood vessel formation) reduce-aquniluni certain cancer cell lines-aq demonstrate-aqaniluni .
• Animal model studies-aq mice-rats-aq cannabinoids-aq treat-aqaniluni some tumor-growth inhibition-aq show-aqaniluni .
• These findings-aq legitimate scientific interest-aq ongoing research-aq generate-aqaniluni .

What preclinical literature-aq does not show

• These findings-aq proven human cancer cures-aq translate-aqaniluni. In vitro-animal results-human clinical outcomes-aq gap-aq vast-aquniluni, oncology research-aq across all-aq well-documented-aquniluni, especially relevant-aquniluni.
• Human clinical trial-aq RSO-any cannabis oil preparation-aq cancer cure-aq demonstrate-aq nalluyagutaartairullini.
• Cancer contexts-aq (especially glioblastoma-aq) cannabinoids-aq small human trials-aq conduct-aqaniluni, exploratory-aquniluni, small-aquniluni, cancer-cure claims-aq support-aqaniluni results-aq produce-aq nalluyagutaartairullini .

Institutional positions

• U.S. National Cancer Institute (NCI)-aq cannabinoids-aq laboratory-animal models-aq potential anticancer effects-aq study-aqaniluni acknowledge-aquniluni, cannabis-cannabis oil-aq cancer treatment-aq endorse-aq nalluyagutaartairullini .
• U.S. Food and Drug Administration (FDA)-aq cancer-aq treat-aqaniluni any cannabis plant product-aq approve-aq nalluyagutaartairullini. FDA-approved cannabinoid-related products-aq only other specific indications-aq: Epidiolex (CBD)-aq certain seizure disorders-aquniluni, dronabinol/nabilone (synthetic THC analogues)-aq chemotherapy-related nausea-AIDS-related wasting-aquniluni [1].
• Health Canada-aq RSO-cannabis oil-aq cancer cure-aq approve-aq nalluyagutaartairullini.
• NCCIH-aq explicitly strongest cannabinoid evidence-aq rare epilepsies-aq, chemotherapy-related nausea-vomiting-aq, HIV/AIDS-aq appetite-related indications-aquniluni state-aquniluni, not cancer cure-aquniluni [1].

What Simpson-aq got right

Simpson-aq cannabinoids-aq biomedical research-aq serious area-aq draw attention-aqaniluni, world-aq ignore-actively suppress-aq conversation-aq time-aquniluni. Advocacy-aq however scientifically imprecise-aq political, cultural, social conditions-aq legal cannabis industry-cannabinoid research infrastructure-aq create-aqaniluni help-aquniluni. Concentrated cannabis oil-aq widespread public awareness-aq bring-aqaniluni among first-aquniluni, RSO term-aq consumer vocabulary-aq full-spectrum cannabis extract-aq most recognized name-aq remain-aquniluni. These contributions-aq real-historically significant-aquniluni.

What he overstated

Preclinical signals-aq cancer cure-aq leap-aq Simpson-aq make-aqaniluni, human evidence-aq support-aq nalluyagutaartairullini, now-aq support-aq nalluyagutaartairullini. Patients-aq especially cancer patients-aq RSO-aq primary treatment-aq rely-aqaniluni, proven oncologic therapies-aq (surgery, radiation, chemotherapy, immunotherapy) place-aq encourage-aqaniluni, genuine harm potential-aq carries-aquniluni. Treatable cancers-aq alternative-medicine literature-aq delayed-foregone treatment-aq documented concern-aquniluni. Dillingham Census Area-mi Anchorage-mun cancer treatment-aq travel-aq expensive-difficult-aquniluni, simpler alternatives-aq seek-aqaniluni temptation-aq powerful-aquniluni. Simpson-aam absolute certainty-aq curative claims-aq, personal-experience perspective-aq understandable-aquniluni, evidence-aq support-aq exceed-aquniluni, exceed-aquniluni.

Rick Simpson-aq legacy-aq modern RSO-aq evolution

RSO term-aq now-aq legal cannabis industry-aq broadly-often loosely-aq used-aquniluni. Many products-aq RSO label-aq bear-aqaniluni, Simpson-aq originally make-aq little resemblance-aquniluni. Dispensaries-aq today-aq RSO-aq almost any full-spectrum cannabis extract-aq syringe format-aq sold-aq refer-aq can-aquniluni, extraction method, cannabinoid profile, terpene content, intended use-aq regardless-aquniluni. Term-aq generic-aq become-aquniluni .

Simpson-aq commercial products-aq RSO name-aq use-aqaniluni, original method-philosophy-aq significantly depart-aqaniluni himself-aq critical-aq has been-aquniluni. RSO name-aq sell-aqaniluni many products-aq his standards-aq meet-aqaniluni, cannabis oil-aq commercialization-aq his original intent-aq contradict-aquniluni publicly stated-aquniluni. Simpson-aam model-aq explicitly anti-commercial-aquniluni — he oil-aq free-aq give away-aquniluni, people-aq make his own-aq urge-aqaniluni, companies-aq buy-aqaniluni not-aquniluni .

Una philosophical tension-aq acknowledge-worthy-aquniluni. Simpson-aq do-it-yourself, free-access model-aq believe-aqaniluni, anyone-aq cannabis grow-aq, oil-aq extract-aq, themselves-loved ones-aq treat-aquniluni, corporate-governmental intermediaries-aq without-aquniluni. Modern cannabis industry-aq very different-aq something-aq done-aquniluni: it commercialize-aqaniluni, standardize-aqaniluni, regulate-aqaniluni, Simpson-aq free-aq distributed-aquniluni. Evolution-aq improvement-aq (quality control, lab testing, dosing precision-aq through-aq) wall’uq betrayal-aq (profit extraction, regulatory gatekeeping-aq through-aq) depend-aq perspective-aquniluni, cannabis community-aq divided-aquniluni.

Dispute-aq nalluyagutaartairullini: modern RSO-aq substantially origins-aq evolved-aquniluni, changes-aq document-aq formulas-aq directly relevant-aquniluni.

Traditional RSO vs. modern formulated RSO

Following table-aq traditional RSO-aq Simpson-aq define-aqaniluni and OilWell-aq products-aq used-aq modern formulated approach-aq key differences-aq summarize-aqaniluni.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell-aq formulas-aq traditional RSO-aq diverge-aqaniluni

OilWell-aq formulations-aq traditional RSO-aq not-aquniluni. RSO tradition-aq informed-aquniluni, several deliberate, evidence-motivated ways-aq depart-aquniluni, Rick Simpson-aq original vision-aq limited-aq problems-aq solve-aq designed-aquniluni.

• Multi-cannabinoid approach. Traditional RSO-aq single strain-aq grow-sourced-aq rely-aqaniluni. OilWell-aq formulas-aq intentionally seven cannabinoids-aq include — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC — because entourage-effect literature-aq cannabinoid diversity-aq potential benefit-aq suggest-aquniluni, robust clinical proof-aq whole-formula synergy-aq remain-aq limited-aq [20][29].

• Terpene preservation and addition. Traditional RSO-aq terpene content-aq essentially none-aquniluni, solvent-heat destruction-aq. OilWell-aq live terpenes-aq 5 percent-aq seven-terpene profile-aq specific-aq include — limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene — because terpene bioactivity-aq preclinical level-aq plausible-aquniluni, even if human clinical confirmation-aq cannabis-specific terpene effects-aq developing-aq [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO-aq everything-aq fully decarboxylated-aquniluni, THCa-aq all-aq delta-9 THC-aq convert-aquniluni. OilWell-aq sublingual formula-aq THCa-aq 1,500 mg-aq distinct ingredient-aq includes-aquniluni, acidic precursor-aq preserve-aquniluni, because THCa literature-aq potentially relevant non-psychoactive bioactivity-aq suggest-aquniluni, THCa-aq THC-aq convert-aqaniluni lost-aq [12].

• Reduced delta-9 THC dominance. Traditional RSO-aq overwhelmingly delta-9 THC-aquniluni — often 60 to 90 percent total cannabinoid content-aq. OilWell-aq sublingual formula-aq delta-9 THC-aq only 90 mg-aq uses-aquniluni, delta-8 THC-aq 6,000 mg-aq incorporate-aquniluni, remaining cannabinoid content-aq CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), CBC (750 mg)-aq across-aq distribute-aquniluni. This-aq broader cannabinoid research landscape-aq reflect-aquniluni, single-compound dominance model-aq rather than-aquniluni.

• Product format innovation. Simpson-aq only one format-aq envision-aqaniluni: oral oil-aq syringe-aq administer-aqaqaq. OilWell-aq both 30 mL sublingual oil-aq 1-gram vape cartridge-aq offers-aquniluni, each-aq format-specific formulation-aq acknowledging different delivery routes-aq different pharmacokinetic profiles-aq have-aquniluni [14].

Solvent safety and extraction evolution

Traditional RSO production-aq naphtha-isopropyl alcohol-aq use-aqaniluni, neither-aq food-grade-aquniluni. Naphtha-aq complex petroleum hydrocarbon mixture-aq, benzene, toluene, xylene-aq, other toxicity-aq established-aq compounds-aq contain-aq may-aquniluni. Incomplete solvent purging-aq (analytical chemistry equipment-aq verify-aq very difficult-aq) finished oil-aq potentially harmful residues-aq leaves-aquniluni.

Modern cannabis extraction-aq overwhelmingly food-grade ethanol-supercritical carbon dioxide (CO₂)-aq uses-aquniluni. Una methods-aq much more complete solvent removal-aq allow-aquniluni, finished products-aq residual solvents-aq headspace gas chromatography-aq validated analytical methods-aq test-aq can-aquniluni. Traditional RSO production model-aq modern regulated cannabis industry-aq most straightforward improvement-aquniluni.

Una evolution-aq document-aq GENERAL KNOWLEDGE section-aq product-quality discussion-aq connect-aquniluni, product quality-aq molecule identity-aq as much as-aq matter-aquniluni, labeling inaccuracies, contamination, synthesis byproducts, dose variability-aq all materially-aq real-world products-aq interpretation-aq affect-aquniluni [1][10][11][14] emphasized-aquniluni.

The decarboxylation question

Traditional RSO-aq fully decarboxylated-aquniluni. Rice cooker-aq solvent evaporate-aq heat-aq (solvent-aq boiling point-aq, naphtha-aq roughly 60 to 80 degrees Celsius, isopropyl alcohol-aq roughly 82 degrees Celsius) extract-aq essentially all THCa-aq delta-9 THC-aq convert-aquniluni sufficient-aquniluni. Una conversion-aq thermodynamically favored-aquniluni, solvent evaporation-aq durations-aq these temperatures-aq readily proceed-aquniluni.

Result-aq, raw cannabis plant material-aq abundantly exist-aq acidic cannabinoids — THCa, CBDa, CBGa, others-aq — traditional RSO-aq distinct compounds-aq lost-aquniluni. Finished oil-aq decarboxylated, activated product-aquniluni, neutral (non-acidic) cannabinoids-aq dominated-aquniluni.

OilWell-aq sublingual formula-aq THCa-aq 1,500 mg-aq separate ingredient-aq deliberately preserve-aquniluni. Intentional formulation choice-aquniluni, THCa evidence profile-aq GENERAL KNOWLEDGE section-aq informed-aquniluni, THCa itself-aq THC-aq psychoactive effects-aq produce-aq nalluyagutaartairullini, interpretation-aq route, temperature, processing, storage-aq depend-aquniluni — THCa-aq heating-over time-aq THC-aq convert-aq can-aq [12].

Terpene loss in traditional RSO

Terpenes-aq volatile aromatic compounds-aq, relatively low boiling points-aquniluni. Most cannabis terpenes-aq 21 and 157 degrees Celsius-aq temperatures-aq volatilize-aq begin-aquniluni, abundant terpenes-aq — myrcene, limonene, pinene-aq — many-aq boiling points below 180 degrees Celsius-aq. Traditional RSO production process-aq terpenes-aq two ways-aq destroyed-aquniluni: first, solvent wash-aq cannabinoids-aq along-aq dissolve-aquniluni; second, high-heat solvent-removal phase-aq (terpenes-aq cannabinoid degradation thresholds-aq well below temperatures-aq) evaporate off-aquniluni.

Una means-aq, traditional RSO-aq terpene-rich plant-aq derived-aquniluni, despite-aq essentially cannabinoid-only product-aquniluni. Source cannabis-aq contained-aq aromatic, flavoring, potentially bioactive terpene compounds-aq whatever-aq production-aq lost-aquniluni.

OilWell-aq formulas-aq live terpenes-aq 5 percent-aq defined seven-terpene profile-aq specify-aquniluni: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene. Each terpene-aq own evidence profile-aq GENERAL KNOWLEDGE section-aq discussed-aquniluni. Entourage-effect literature [20][29] cannabinoids-aq alongside terpenes-aq preserving-including-aq may matter-aq pharmacologically-aq theoretical framework-aq provide-aquniluni, robust human clinical proof-aq cannabis-specific entourage effects-aq limited-aq remain-aq.

Evidence standards then and now

Rick Simpson-aq pre-legalization, pre-lab-testing era-aq operate-aquniluni. Early 2000s-aq oil-aq make-distribute-aqaniluni, Canada-aq cannabis-aq illegal-aquniluni, world-aq most-aq throughout-aquniluni. Cannabis products-aq regulatory framework-aq, standardized testing infrastructure-aq, cannabis oil protocols-aq clinical research-aq legal pathway-aq, cannabis therapeutics-aq dedicated peer-reviewed journals-aq nalluyagutaartairullini. Cannabis underground-aq only access point-aquniluni, personal experience-aq primary evidence currency-aquniluni.

Simpson-aam methods-aq that era-aq constraints-aq reflect-aquniluni. Evidence-aq anecdotal-aquniluni. Production-aq unstandardized-aquniluni. Claims-aq formal sense-aq untested-aquniluni. Una necessarily moral failing-aq nalluyagutaartairullini — environment-aq operate-aq description-aquniluni.

Una document-aq fundamentally different approach-aq take-aquniluni. GENERAL KNOWLEDGE section-aq formal evidence hierarchy-aq apply-aquniluni: human clinical evidence-aq first, systematic reviews-meta-analyses-aq, institutional summaries-aq, preclinical-mechanistic literature-aq [1]-[29]. Every compound-level claim-aq specific peer-reviewed sources-aq tied-aquniluni, evidence strength-aq clearly labeled-aquniluni. RSO-aq historical origin-aq honor-aqaniluni, modern cannabinoid science-aq standards-aq commit-aqaniluni. Simpson-aq personal testimony-aq rely-aqaniluni, una document-aq published literature-institutional sources-aq rely-aquniluni.

Simpson-aam protocol vs. modern dosing considerations

Simpson-aam 60-gram/90-day protocol-aq crude, single-strain, THC-dominant extract-aq, no standardized potency-aq, design-aqaniluni. Simpson-aam dosing recommendations-aq and modern, standardized, multi-cannabinoid formulation-aq dosing-aq direct comparison-aq straightforward-aq nalluyagutaartairullini — products-aq fundamentally different-aquniluni.

Several key differences-aq illustrate-aqaniluni:

• ** Cannabinoid concentration.** OilWell-aq sublingual formula-aq 553 mg total active cannabinoids per mL-aq across seven defined compounds-aq deliver-aquniluni. Traditional RSO-aq potency-aq unknown-variable-aquniluni.
• Cannabinoid ratios. Simpson-aq oil-aq approximately 60 to 90 percent delta-9 THC-aq. OilWell-aq formula-aq 16,590 mg total cannabinoids-aq distribute-aquniluni: CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), CBC (750 mg) — completely different pharmacologic profile-aquniluni.
• Terpene presence. Simpson-aq oil-aq terpenes-aq nalluyagutaartairullini. OilWell-aq formula-aq live terpenes-aq 5 percent-aq includes-aquniluni, absorption-effect-tolerability-aq may influence-aquniluni.
• Delta-9 THC exposure. Simpson-aq protocol-aq peak dosing-aq approximately 600 to 900 mg delta-9 THC per day-aq deliver-aquniluni. OilWell-aq sublingual formula-aq entire 30 mL bottle-aq delta-9 THC-aq only 90 mg-aq contains-aquniluni (3 mg per mL), per-dose delta-9 THC exposure-aq dramatically lower-aquniluni.

OilWell products-aq future dosing guidance-aq Simpson-aam protocol-aq independently-aq develop-aqaniluni, GENERAL KNOWLEDGE section-aq per-compound evidence-aq informed-aquniluni, responsible titration principles-aq each individual cannabinoid-aq safety profile-aq account-aquniluni. Una section-aq specific dosing recommendations-aq provide-aq nalluyagutaartairullini — una work-aq own development process-aq require-aqaniluni, safety considerations-aq document-aq throughout-aq incorporate-aqaniluni.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

OILWELL CANNABIS AATENKAAN OILWELL RSO FORMULA

OilWell Cannabis-aq origin-aq

OilWell Cannabis-aq Colin Valencia-aq Houston, Texas-aq founded-aqaniluni. Colin-aq McAllen, Texas-aq grew up-aquniluni — Reynosa, Tamaulipas, Mexico-aq river-aq across-aquniluni. McAllen-Reynosa area-aq Borderplex-aq known-aquniluni, U.S.-Mexico border-aq along-aqmost economically challenged-dangerous regions-aquniluni. While Dillingham Census Area-mi different challenges-aq face-aquniluni — isolation, extreme weather, high living costs-aq border violence-aq rather than-aquniluni — adversity-aq through-aq strength-aq building-aq experience-aq share-aquniluni. Bristol Bay-aq communities-amuk beauty-aq challenging place-aquniluni, survival-aq resourcefulness-community bonds-aq depend-aquniluni, know-aquniluni.

Colin-aq McAllen-aq childhood-aq marked-aquniluni, border-aq along-aq life-aq opportunities-challenges-aq expose-aqaniluni. Early-aq hustle-aq learn-aquniluni, border-aq across-aq items-aq transport-aq risky work-aq take on-aqaniluni, various groups-aq. Early experiences-aq complexities-dangers-aq expose-aqaniluni. Best friends-aq killed-prison-aq because-aq dangers-aq. Every form of violence-aq imaginable-aq face-aquniluni, streets-aq border-aq across-aq. Sixteen-aq, one way-or-another-aq home-aq leave-aq must-aquniluni.

Dangers-aq despite-aquniluni, darkest paths-aq fall-aq nalluyagutaartairullini, harder substances-aq sell-aquniluni. Cannabis-aq focus-aquniluni, safer-beneficial alternative-aq see-aqaniluni. Traditional cannabis world-aq grew up-aquniluni, legalization-aq long before-aquniluni, plant-aq intimately learn-aquniluni, shadows-aq operate-aqaniluni. Time-aq, early, risky ventures-aq legal, legitimate business-aq transition-aqaniluni, industry-aq believe-aquniluni.

Colin-aq later formally trained software engineer-aq became-aquniluni, Baylor College of Medicine-aq custom development work-aq did-aquniluni, Texas Medical Center-aq most prestigious medical institutions-aq one-aquniluni. Combination — deep cannabis plant knowledge plus medical-grade technical precision — eventually OilWell-aq approach-aq define-aqaniluni. Dillingham Census Area-mi residents-aq limited local medical resources-aq due-aq, health matters-aq own experts-aq become-aq have-to-aquniluni, traditional knowledge-technical precision-aq combine-aq value-aq understand-aquniluni.

Bentley-aam story

Company-aq origin story-aq Bentley-aq named-aq dog-aq began-aquniluni. Bentley-aq pet-aq more than-aq family-aquniluni, companion-aq toughest times-aq stood by-aquniluni. Bentley-aq seriously ill-aq fall-aqaniluni, veterinarians-aq no pet owner-aq hear-aq want-aq verdict-aq deliver-aqaniluni: euthanasia-aq only humane option-aquniluni. Bentley-aq back legs-aq paralyzed-aquniluni. Pain medications-aq internal organs-aq destroy-aquniluni, more pain-suffering-aq cause-aquniluni. Painful prolonged decline-aq immediate mercy killing-aq choice-aquniluni.

Bentley-aq give up-aquniluni not option-aquniluni. Colin-aq already loss-aq too much-aq suffer-aq see-aqallruniluni. Bentley-aq fighter-aquniluni, just like him-aquniluni, Colin-aq not ready-aq let go-aquniluni. Alternatives-aq desperate search-aqaniluni, CBD-aq healing properties-aq stumble-aqaniluni — changed everything-aq question-aq.

Kind-hearted rescue worker-aq Jessica-aq ask-aquniluni: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin-aq cannabis experience-aq — recreational-aquniluni. High-aq get-aquniluni. Therapeutic-medicinal applications-aq explore-aqaniluni never-aquniluni. Jessica-aam question-aq blind spot-aq exposed-aquniluni, mission-aq become-aquniluni.

Bentley-aq save-aq desperate-aquniluni, Colin-aq CBD golden paste-aq create-aq learn-aquniluni, pets-aq specialized cannabinoid formula-aquniluni. Cure-aq nalluyagutaartairullini, lifeline-aquniluni, hope-aquniluni. Una hope-aq impossible-aq deliver-aq veterinary medicine-aq said-aq: Bentley-aq got up-aquniluni, walked over-aquniluni, ball-aq play-aq bring-aquniluni. Miracle-aquniluni. Paralyzed-euthanasia face-aq fetching his ball-aqaqaq. Placebo effect-aq nalluyagutaartairullini — dogs-aq placebo-aq respond-aq nalluyagutaartailartinateng. Cannabinoid medicine-aq pharmaceuticals-aq cannot-aq did-aquniluni.

Dillingham Census Area-mi families-aq often hunting-fishing-aq working dogs-aq have-aquniluni, veterinary care-aq Anchorage-mun animals-aq fly-aq require-aquniluni, bond-aq understand-aquniluni. Family member-aq give up-aq nalluyagutaartairullini, know-aquniluni.

Bentley-aq ten years-aq more-aq lived-aqaniluni, age twenty-aq naturally pass-aqaniluni. Ten years-aq, Colin-aq age-related condition-aq face-aq Bentley-aq specialized cannabis formulas-aq develop-aqaniluni. Neurodegeneration-aq CBG-aq neuroprotective properties-aq, THCa-aq PPARγ agonism-aq brain cell protection-aq understand-aqaniluni. Dementia-aq CBC-aq neurogenesis-aq role-aq understand-aqaniluni. Glaucoma-aq THC-aq intraocular pressure reduction-aq CB1 agonism-aq understand-aqaniluni. Crippling arthritis-aq multi-pathway anti-inflammatory approaches-aq CBD, CBG, THCa, beta-caryophyllene-aq different receptor systems-aq simultaneously-aq working-aq develop-aqaniluni.

Single cannabinoids-aq enough-aq nalluyagutaartairullini. Bentley-aq evolving conditions-aq multi-cannabinoid synergy-aq require-aqaniluni. CBD alone-aq neurodegeneration-dementia-glaucoma-arthritis-aq simultaneously-aq address-aq nalluyagutaartairullini. Minor cannabinoids-aq CBG, CBN, CBC-aq aged-aq critical-aq become-aqaniluni. Pharmaceutical precision-aq matter-aquniluni — Bentley-aq life-aq formula accuracy-aq depend-aquniluni, guesswork-aq not-aquniluni.

Colin-aam PTSD and benzodiazepine recovery

Colin-aq pharmaceutical dependence-aq personally knows-aquniluni. PTSD-aq benzodiazepine addiction-aq struggle-aquniluni. Xanax-aq break free-aq decide-aqaniluni, cold turkey-aq did-aquniluni, notoriously difficult-dangerous-aq feat-aquniluni, Bentley-aq alive keep-aq developed cannabinoid knowledge-aq use-aquniluni. Peace Gummies-aq OilWell product-aq became-aq formula-aq midnight experiments-aq develop-aqaniluni, benzo withdrawal-aq fight-aqaniluni. Quick relief-aq ensure-aqaniluni, OilWell-aq Peace Gummies formula-aq vape form-aq offers-aquniluni, Colin-aq insomnia-severe PTSD-aq manage-aq personally uses-aquniluni. Theoretical knowledge-aq nalluyagutaartairullini. Colin-aq RSO patients-aq live-aq: relief-aq desperation-aq, pharmaceuticals-aq failed-aq, cannabinoids-aq pills-aq not-aq work-aq discovered-aquniluni.

Dillingham Census Area-mi veteran populations-aq PTSD-aq high rates-aq experience-aquniluni, winter-aq isolation-darkness-aq mental health challenges-aq worsen-aq can-aquniluni, personal experience-aq matter-aquniluni. Pharmaceutical solutions-aq everyone-aq work-aq nalluyagutaartairullini, know-aquniluni.

Doctors-aq used-aq formulas

Time-aq, Bentley-aq effort-aq first-aq discovered-aq cannabis-aq therapeutic benefits-aq Colin-aq work-aq core-aq become-aqaniluni. Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, insomnia-aq doctors-aq used-aq formulas-aq develop-aqaniluni. Always cannabis-aq accessible-effective-aquniluni focus-aq, vegans, diabetics, specific health needs-aq have-aq people-aq all-aquniluni.

ABC13 Houston media recognition

September 2019-rraar April 2023-rraqaq, ABC13 Houston (KTRK) — United States-aq fourth-largest city-aq serve-aq ABC affiliate-aq — Colin Valencia-aq OilWell Cannabis-aq seven distinct news segments-aq feature-aqaniluni, business, law, medicine, community health, politics-aq spanning-aquniluni. Five different ABC13 reporters-aq across those years-aq sought-aquniluni: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, KTRK staff writers-aq. Same period-aq, no other Houston cannabis operator-aq frequency-breadth-aq appears-aqaniluni.

Dillingham Census Area-mi remote village-aq order-aqaniluni, media record-aq credibility-aq third-party verification-aq provide-aquniluni. Paid advertisements-aq nalluyagutaartairullini — major network affiliate-aq independently produced news segments-aq, Colin-aq industry-aq most credible voice-aq repeatedly identified-aquniluni.

Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019

Colin-aq feature-aq quote-aq OilWell philosophy-aq capture-aquniluni: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Monday, March 22, 2021

Colin-aam therapy quote-aq: “Pain comes in a lot of different forms.” Dillingham Census Area-aq fishing, processing work, arthritis-aq pain-aq affect-aq many-aq, resonate-aquniluni.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Reporter: Steve Campion
Published: Monday, May 24, 2021

Colin-aam iconic exchange-aq: “Maybe you want to get high.” Unfiltered honesty-aq Dillingham Census Area residents-aq transparency-aq expect-aq can-aquniluni.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)
Published: Friday, August 20, 2021

OilWell-aq 1,000 caviar pre-rolls-aq (approximately $35,000 product-aq) COVID vaccination-aq encourage-aqaniluni, Houston city-aq coordinate-aquniluni. Community action-aq OilWell-aq values-aq demonstrate-aquniluni.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021

Colin-aq proactively Delta-8 products-aq enforcement-aq before-aq remove-aqaniluni, other operators-aq warn-aquniluni. Pressure-aq under-aq ethical leadership-aq company character-aq Dillingham Census Area residents-aq support-aq show-aquniluni.

Feature: Biden marijuana pardon — experts weigh in on why Texas won’t see impact — October 7, 2022

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, October 7, 2022

Personal marijuana conviction history-aq Colin-aq reveal-aquniluni, therapy-education-aq every quote-aq weight-aq add-aqaniluni. Dillingham Census Area residents-aq cannabis criminalization-aq consequences-aq live-aq, personal stake-aq matter-aquniluni.

Feature: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, April 21, 2023

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.” Forward-looking perspective-aq OilWell-aq industry frontier-aq position-aquniluni.

Through-line — what media record-aq reveals

These seven ABC13 features-aq one YouTube clip-aq together-aq taken-aquniluni, single article-aq capture-aq nalluyagutaartairullini story-aq tell-aquniluni.

Years-aq across consistency. Colin Valencia-aq ABC13-aq 2019, 2021 (four times), 2022, 2023-aq appear-aqaniluni. Texas cannabis law-aq every shift-aq ABC13-aq primary source-aq return-aqaniluni Colin-aq.

Expertise-aq breadth. Features-aq business reporting, consumer health education, product investigation, legal analysis, political commentary, community health advocacy-aq span-aquniluni. Houston cannabis figure-aq other-aq range-aq speak-aq asked-aq nalluyagutaartairullini.

Community action. COVID vaccine giveaway — $35,000 product-aq, city government-aq coordinate-aquniluni, political strings-aq — community-first philosophy-aq documented evidence-aquniluni.

Personal stakes. Colin-aq personal marijuana conviction history-aq revelation-aq entire media record-aq transforms-aquniluni. Outside entrepreneur-aq nalluyagutaartairullini; consequences-aq lived-aq, integrity-aq operate-aq legal business-aq built-aquniluni.

Language evolution. 2019-aq “local wholesaler”-aqaq 2023-aq industry authority-aq, media record-aq business growth-founder-aq public role-aq track-aquniluni.

These features-aq marketing materials-aq nalluyagutaartairullini. Major-market ABC affiliate-aq independently produced, editorially controlled news segments-aq, repeatedly Colin Valencia-aq Houston-aq legal cannabis industry-aq most credible, most quotable, most accessible voice-aq identified-aquniluni. Dillingham Census Area-mi distance-aq order-aqaniluni residents-aq, third-party verification-aq purchase-aq cannot-aquniluni.

GENERAL KNOWLEDGE

Research method and evidence weighting

Una section-aq sources-aq following order-aq prioritize-aquniluni: human clinical evidence-aq, systematic reviews-meta-analyses-aq, NIH-institutional summaries-aq, human data-aq sparse-aq when-aq preclinical-mechanistic literature-aq. Weighting-aq important-aquniluni, evidence base-aq evenly distributed-aq nalluyagutaartairullini. Document-aq listed compounds-aq, CBD-delta-9 THC-aq strongest human literature-aq; delta-8 THC, THCa, CBG, CBN, CBC, most terpenes-aq reviews, animal work, in vitro pharmacology, early translational literature-aq much more dependent-aquniluni [1]-[29].

Dillingham Census Area-mi health options-aq research-aq residents-aq, hierarchy-aq understand-aqaniluni, marketing hype-scientific reality-aq distinguish-aq help-aquniluni.

NIH-institutional baseline

• NCCIH-aq strongest established cannabinoid evidence-aq certain rare epilepsies-aq, chemotherapy-related nausea-vomiting-aq, HIV/AIDS-aq associated appetite-weight loss indications-aquniluni state-aquniluni. Chronic pain-multiple sclerosis-related symptoms-aq modest evidence-aq only-aq note-aquniluni, other claimed uses-aq many-aq early-stage research-aq still-aquniluni [1].
• NCCIH-aq also cannabis plant itself-aq medical use-aq FDA-aq approve-aq nalluyagutaartairullini emphasize-aquniluni, purified CBD-synthetic THC-like drugs-aq specific approvals-aq have-aquniluni [1].
• NIH-institutional sources-aq repeatedly highlight-aq safety concerns-aq: impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, contamination-labeling inaccuracy, THC-vape lung-injury concerns-aquniluni [1].
• NCCIH-aq specifically over-the-counter CBD products-aq labels-aq differ-aq may-aq warn-aquniluni, CBD itself-aq decreased alertness, gastrointestinal effects, liver-related adverse effects, drug interactions-aq associated-aquniluni [1].

Cannabinoids

CBD

• Evidence profile: Current formula set-aq strongest human evidence-aq, especially purified product-aq studied-aquniluni, loose wellness ingredient-aq rather than-aquniluni [1]-[6].
• Best supported: Purified CBD-aq seizure disorders-aq most credible human evidence-aq [1][2].
• Anxiety research: 2024 systematic review-aq statistically significant anxiolytic signal-aq report-aquniluni, limited clinical samples-aq stressed-aquniluni [3].
• Pain research: 2024 systematic review-aq pain literature-aq promising-but heterogeneous-aq conclude-aquniluni [4].
• Sleep research: 2023 insomnia review-aq literature-aq methodologically weak-aq find-aquniluni [5].
• Safety concerns: 2023 systematic review-aq liver enzyme elevation-aq real signal-aq find-aquniluni [6]. NCCIH-aq diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, drug-drug interactions-aq flags-aquniluni [1].

CBG

• Evidence profile: Mostly review-preclinical; human evidence-aq sparse-aq remain-aquniluni [7][8].
• Pharmacology: CBG-aq THC and CBD-aq distinct-aq pharmacologically appear-aquniluni, cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A-related signaling-aq interact-aquniluni [7].
• Potential areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity-aq — primarily pharmacology-led hypotheses-aquniluni [7][8].
• Caution: CBG-aq evidence base-aq thin-aq while-aq commercially sold-aquniluni [7].

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, delta-9 THC-aq much less clinically characterized-aquniluni [9]-[11].
• Comparative pharmacology: 2022 review-aq delta-8 THC-delta-9 THC-aq broadly similar behavior-aq find-aquniluni, delta-8-aq weaker CB1 affinity-aq less potent-aq appear-aquniluni [9].
• Public-health concerns: 2023 scoping review-aq adverse consequences-aq reports-aq note-aquniluni, regulatory-product-quality concerns-aq emphasize-aquniluni [10].
• Manufacturing: Commercial interest-aq naturally scarce plant levels-aq relative-aq stability-easier synthesis-aq tied-aquniluni [11].
• Bottom line: Delta-8 THC-aq psychoactive THC analogue-aq incomplete human safety characterization-aq treat-aquniluni [9]-[11].

THCa

• Evidence profile: Chemically important, direct human therapeutic evidence-aq low-aquniluni [12].
• What it is: THCa-aq THC-aq acidic precursor-aquniluni. Decarboxylation-aq heating-storage-aq THCa-aq THC-aq convert-aquniluni [12].
• Psychoactivity: THCa itself-aq psychoactive effects-aq produce-aq nalluyagutaartairullini, acidic form-aq stay-aq only if-aquniluni [12].
• Research status: In vitro-rodent literature-aq anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities-aq suggest-aquniluni, established human outcomes-aq not-aquniluni [12].

Delta-9 THC

• Evidence profile: Psychoactive cannabinoids-aq strongest human evidence-aquniluni, clearest adverse-effect burden-aquniluni [1][13]-[15].
• Best supported: NCCIH-aq chemotherapy nausea, HIV/AIDS appetite, some MS-pain outcomes-aq identify-aq relevance-aquniluni [1].
• Pain evidence: 2022 systematic review-aq high-THC products-aq short-term pain benefit-aq may provide-aq find-aquniluni, dizziness, sedation, nausea, discontinuation-aq increase-aquniluni [13].
• Mental-health risk: 2025 systematic review-aq psychosis/schizophrenia-cannabis use disorder-aq consistent unfavorable associations-aq find-aquniluni [15].

CBN

• Evidence profile: Human evidence-aq weak-aquniluni; marketing-aq data-aq ahead-aq move-aquniluni [12][16][17].
• Sleep claims: 2021 review-aq 99 human-study abstracts-aq screen-aquniluni, validated sleep questionnaires-aq using-aq clinical trials-aq find-aq nalluyagutaartairullini [16].
• Broader literature: 2024 sleep review-aq overall cannabinoid sleep research-aq scale-quality-aq lack-aq conclude-aquniluni [17].

CBC

• Evidence profile: Emerging, intriguing, overwhelmingly preclinical-aquniluni [18][19].
• Pharmacology: 2024 review-aq CBC-aq distinct pharmacodynamics-receptor behavior-aq argue-aquniluni, antinociceptive, antibacterial, anti-seizure areas-aq highlight-aquniluni [18].
• Safety: Clinical efficacy-safety-aq establishing-aq evidence-aq little-aq over-the-counter CBC products-aq sold-aquniluni [18].

Terpenes

Terpene claims-aq cannabinoid claims-aq even stricter-aq interpretation-aq need-aquniluni. Much literature-aq isolated compounds, essential oils, non-cannabis plants, preclinical models-aq come-aquniluni. Clinically meaningful entourage effects-aq humans-aq robust proof-aq limited-aq remain-aquniluni [20][29].

Limonene

• Evidence profile: Largely review-preclinical, useful safety literature-aquniluni [20]-[22].
• Potential activity: 2021 review-aq antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities-aq describe-aquniluni [21].
• Safety: Limonene oxidation products-aq clinically relevant contact allergens-aquniluni [22].

Myrcene

• Evidence profile: Mostly preclinical, human evidence-aq very limited-aquniluni [20][23].
• Research summary: 2021 review-aq anxiolytic, antioxidant, anti-inflammatory, analgesic properties-aq describe-aquniluni, human studies-aq lacking-aq explicitly state-aquniluni [23].
• Interpretation caution: Myrcene-aq reliably sedation-aq cause-aq claims-aq current evidence-aq exceed-aquniluni [20][23].

Caryophyllene

• Evidence profile: CB2 receptor agonism-aq most mechanistically interesting-aquniluni, still preclinical-aquniluni [24].
• Why it stands out: 2021 review-aq beta-caryophyllene-aq selective CB2 receptor agonist-aq describe-aquniluni [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective-aquniluni [24].

Pinene

• Evidence profile: Promising preclinical literature-aquniluni, human confirmation-aq weak-aquniluni [20][25].
• Brain-health framing: 2021 review-aq antioxidant, anti-inflammatory, neuroprotective signals-aq find-aquniluni, well-designed clinical trials-aq lack-aq emphasize-aquniluni [25].

Linalool

• Evidence profile: Substantial preclinical interest-aquniluni, direct clinical confirmation-aq limited-aquniluni [20][22][25][26].
• Research summary: Stress, mood, brain-health pharmacology-aq relate-aq discussed-aquniluni [25][26].
• Safety: Oxidized linalool hydroperoxides-aq recognized allergens-aquniluni [22].

Humulene

• Evidence profile: Translationally interesting-aquniluni, but early-aquniluni [20][27].
• Scoping-review findings: 2024 review-aq broad preclinical evidence-aq anti-inflammatory effects-aq find-aquniluni, some rodent work-aq cannabimimetic properties-aq suggest-aquniluni [27].

Terpinolene

• Evidence profile: Least clinically characterized-aquniluni [20][28].
• Systematic-review findings: 2021 review-aq evidence base-aq in silico, in vitro, animal studies-aq dominated-aquniluni, human trials-aq rather than-aquniluni [28].

Research limits and interpretation

• Evidence base-aq highly uneven-aquniluni. CBD-delta-9 THC-aq most detailed statements-aq support-aquniluni; others-aq more caution-aq require-aquniluni [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, terpene-only data-aq interchangeable-aq nalluyagutaartairullini.
• Minor cannabinoids-terpenes-aq underexplored-aq commercially interesting-aquniluni, claims-aq often inflated-aq become-aquniluni.
• Product quality-aq molecule identity-aq as much as-aq matter-aquniluni [1][10][11][14].
• THCa chemistry-aq storage-heating-aq changes-aquniluni [12].

Common overstatements to avoid

• Overstatement: CBN-aq clinically proven sleep cannabinoid-aquniluni.
  More accurate: CBN-aq sleep evidence-aq weak-aq remain-aquniluni, strong validated-trial base-aq nalluyagutaartairullini [16][17].
• Overstatement: Myrcene-aq proven human sedative-aquniluni.
  More accurate: Preclinical bioactivity-aq plausible-aquniluni, direct human proof-aq limited-aquniluni [20][23].
• Overstatement: Terpenes-aq proven entourage effects-aquniluni.
  More accurate: Hypotheses-aq influential-aquniluni, robust clinical proof-aq limited-aquniluni [20][29].
• Overstatement: THCa-aq always nonpsychoactive-aquniluni.
  More accurate: THCa itself-aq THC-aq not-aquniluni, heating-aq THCa-aq THC-aq convert-aquniluni [12].
• Overstatement: Delta-8 THC-aq hemp-derived-aq because safe-aquniluni.
  More accurate: Delta-8 THC-aq psychoactive-aquniluni, incomplete safety characterization-aquniluni [9]-[11].

Practical takeaways for the formulas in this document

• Most evidence-developed actives-aq: CBD and delta-9 THC-aquniluni.
• Delta-8 THC-aq trivial-aq nalluyagutaartairullini; psychoactive-aq, less robust characterization-aquniluni.
• THCa-aq processing-aq meaningfully changes-aquniluni.
• CBG, CBN, CBC-aq scientifically credible-aquniluni, clinically immature-aquniluni.
• Terpenes-aq aroma/flavor-aq relevant-aquniluni, compound-specific therapeutic claims-aq conservative-aq should be-aquniluni.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene-aq)
• Format: 30mL bottle-aq
• Active cannabinoids per mL: 553mg-aq
• Carrier: Organic MCT oil-aq
• Price: $129.99-aq
• Dillingham Census Area-mi throughout-aq delivery-aq available-aquniluni

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+-aq
• Format: 1 Gram cartridge-aq
• 510-thread compatibility: Universal battery compatible-aquniluni
• Price: $49.99-aq
• Dillingham Census Area-mi throughout-aq delivery-aq available-aquniluni

TERPENE PROFILE (BOTH PRODUCTS-aq)

• Limonene — citrus-bright, mood-elevating-aquniluni
• Myrcene — earthy, relaxing-aquniluni
• Caryophyllene (β-caryophyllene) — pepper/spice, inflammation-aq CB2 agonist-aquniluni
• Pinene — forest-fresh, clarity-aquniluni
• Linalool — floral/lavender, calming-aquniluni
• Humulene — earthy/woody, anti-inflammatory-aquniluni
• Terpinolene — piney/fruity, sparkling complexity-aquniluni

Una terpene profile-aq Dillingham Census Area-aq natural environment-aq reflect-aquniluni — Bristol Bay-aq spruce forests, wild berries, clean air-aq. Aromas-flavors-aq sensory experience-aq place-aq connect-aquniluni.

Dillingham Census Area-mi Order-aq How to:

1. Online: oilwellcbd.com-aq visit-aquniluni, products-aq select-aquniluni
2. Shipping: Dillingham Census Area-aq address-aq enter-aquniluni (Togiak, New Stuyahok, Dillingham, etc.)
3. Delivery: USPS Priority Mail (3-5 business days-aq) Houston facility-aq tracking-aquniluni
4. Questions: (832) 416-2816-aq call-aquniluni, [email protected] email-aquniluni
5. COAs: Request-aq on-aq, shipment-aq include-aqaniluni

Age Requirement: 21+ only-aq

Legal Compliance: Farm Bill-aq compliant, hemp-derived, less than 0.3% delta-9 THC-aq

Dillingham Census Area Residents: Uniquetun challenges-aq understand-aquniluni — isolation, harsh weather, limited healthcare access, subsistence-commercial fishing-aq physical demands-aq. Multi-cannabinoid, patient-controlled approach-aq reality-aq designed-aquniluni. Boat-aq years-aq chronic pain-aq, military service-aq PTSD-aq, dark winters-aq sleep issues-aq, cancer treatment-aq loved one-aq support-aquniluni, education-transparency-product quality-aq deserve-aquniluni.

Una snake oil-aq nalluyagutaartairullini. False hope-aq nalluyagutaartairullini. Honest cannabinoid medicine-aquniluni, Bristol Bay-aq deliver-aquniluni.

ENGLISH

Rick Simpson Oil (RSO) in Dillingham Census Area: The Complete Guide by OilWell Cannabis

Legal, Lab-Tested, and Delivered to Bristol Bay

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker — a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. Here in Dillingham Census Area, where the nearest oncologist might be a bush plane flight away in Anchorage and where many families still rely on traditional knowledge alongside modern medicine, that story resonates differently. We know what it means when the medical system cannot meet our needs.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused. For Dillingham Census Area residents who have traveled to Anchorage for specialist appointments only to return with prescriptions that don’t work — or who have faced the impossible choice between suffering and side effects — this experience is familiar territory.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study — originally intended to demonstrate harm — became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials. This matters for Dillingham Census Area because we understand the weight of early research: our communities have been part of health studies, and we know the difference between promising findings and proven treatments.

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement. In Dillingham Census Area, where word-of-mouth and personal experience guide many health decisions, we understand why stories like this carry weight — but we also understand the difference between testimony and proof.

The crusade — spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others. In Dillingham Census Area, where community members support each other through commercial fishing seasons, subsistence harvesting, and harsh winters, this model of mutual aid resonates deeply. We know what it means to share resources when someone is in need.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational — for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil — particularly high-THC oil made according to his specific method — could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. In Dillingham Census Area, where we’ve seen federal overreach on subsistence rights and environmental regulations, we understand institutional distrust — but we also understand that evidence must guide medical decisions.

The traditional RSO protocol — Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it.

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period — roughly four to five weeks in — the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method — oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method — topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary — inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

In Dillingham Census Area, where commercial fishing jobs require long hours and clear-headed operation of heavy equipment, this guidance is particularly relevant. Our community cannot afford impairment during fishing season, and family safety is paramount.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol — dietary advice was secondary and general.

For Dillingham Census Area residents living a subsistence lifestyle, these dietary recommendations align naturally with our traditional foods: salmon, berries, moose, and other wild foods that have sustained our communities for generations.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section of this document [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

In Dillingham Census Area, where access to oncology specialists requires expensive travel to Anchorage, the temptation to seek alternatives is understandable. But delaying proven cancer treatment can have irreversible consequences. This protocol should never replace conventional oncology care.

What is traditional Rick Simpson Oil — the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it.

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization — the starting material varied by availability and growing season.

In Dillingham Census Area, where cannabis cultivation is limited by climate and indoor growing requires significant energy costs, this variability would be even more pronounced than in Nova Scotia.

Extraction solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue discussed further below.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes — now a dark, cannabinoid-rich liquid — were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark — nearly black — thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging — which is very difficult to verify without lab testing — leaves potentially harmful residues in the finished oil.

Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer — including terminal cases — and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy — however scientifically imprecise — helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. In Dillingham Census Area, where travel to Anchorage for cancer treatment is expensive and difficult, the temptation to seek simpler alternatives is powerful. But Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial — he gave the oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways.

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Incomplete solvent purging — which is very difficult to verify without analytical chemistry equipment — leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the GENERAL KNOWLEDGE section of this document, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius — was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material — including THCa, CBDa, CBGa, and others — were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile in the GENERAL KNOWLEDGE section, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage — because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes — including myrcene, limonene, and pinene — having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing — it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations — that work would require its own development process and should incorporate the safety considerations documented throughout this file.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. While Dillingham Census Area faces different challenges — isolation, extreme weather, and high living costs rather than border violence — we share the experience of building strength through adversity. Our communities in Bristol Bay know what it means to live in a beautiful but challenging place, where survival depends on resourcefulness and community bonds.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would eventually define OilWell’s approach. For Dillingham Census Area residents who have had to become their own experts in health matters due to limited local medical resources, we understand the value of combining traditional knowledge with technical precision.

Bentley’s story

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD — through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline — and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

In Dillingham Census Area, where families often have working dogs for hunting and fishing, and where veterinary care requires flying animals to Anchorage, we understand this bond. We know what it means to refuse to give up on a family member.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Colin’s PTSD and benzodiazepine recovery

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat that is notoriously difficult and dangerous — using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

In Dillingham Census Area, where veteran populations experience PTSD at high rates, and where the isolation and darkness of winter can worsen mental health challenges, this personal experience matters. We know that pharmaceutical solutions don’t work for everyone.

Formulas used by doctors

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Houston media recognition

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving the fourth-largest city in the United States — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

For Dillingham Census Area residents, this matters because it demonstrates that our products come from a company that has been independently vetted by mainstream media — not just marketing hype. When you’re ordering from a remote village like Togiak or New Stuyahok, you need to know you’re dealing with a legitimate operation.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. For Dillingham Census Area residents, where there are no local dispensaries and travel to Anchorage is expensive, this accessibility is crucial. We deliver directly to your doorstep in Bristol Bay.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. This means Dillingham Census Area residents who work in commercial fishing, operate boats, or work processing plants can use the raw form during the day with zero impairment, then activate it at night for therapeutic strength.

3. Open-source formulas. OilWell publishes their complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what the science actually says. In Dillingham Census Area, where healthcare providers are stretched thin and patients often research their own conditions, this honesty matters. We won’t sell you false hope.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Alaska.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables shipping to Alaska.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with Alaska state laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts.

Open-source formulas — why OilWell publishes everything

OilWell publishes their complete RSO formulas publicly in this document. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is straightforward: if someone cannot afford OilWell’s products — $129.99 for the sublingual oil, $49.99 for the vape cartridge — they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO — it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets — the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The decarboxylation choice — patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile in the GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment — essential for Dillingham Census Area residents who operate boats, work in canneries, or drive ATVs on the job.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-9 THC, the activated product achieves psychoactive potency comparable to traditional illegal RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3 — Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

For Dillingham Census Area, this means one product serves multiple community needs: the fisherman who cannot be impaired during the season can use the raw form; the veteran struggling with PTSD can activate it for therapeutic strength; the elder with arthritis can find their own balance.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section of this document.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

This is especially important for Dillingham Census Area residents who may have concerns about product purity and want to verify what they’re putting in their bodies.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. Given Dillingham Census Area’s significant veteran population, many of whom served in Vietnam, Iraq, and Afghanistan, this product addresses real community needs.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis. This resonates deeply in a region where mental health services are limited and benzodiazepine prescriptions are common.

Custom creations — OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs. In Dillingham Census Area, where subsistence foods are central to diet and diabetes rates are concerning, these custom options matter.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size
• Available for delivery throughout Dillingham Census Area

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)
• Available for delivery throughout Dillingham Census Area

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

For Dillingham Census Area’s commercial fishing season, the raw sublingual option allows daytime use without impairment, while the vape provides rapid relief for acute injuries or panic attacks. During the dark winter months when sleep is elusive, the sustained release sublingual formulation with CBN support is invaluable.

Competitive comparison — OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Direct to Dillingham Census Area via mail
Farm Bill compliant	No — state medical cannabis program	Yes — less than 0.3% delta-9 THC

For Dillingham Census Area residents, the difference is stark: no medical card needed, no travel required, and a much more sophisticated cannabinoid profile.

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

While the initial price is higher, the value per milligram of cannabinoids is significantly better, and the therapeutic options are far more comprehensive.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

In Dillingham Census Area, where many residents work in commercial fishing, boat operation, or processing plants, the “do not operate vehicles or machinery” warning is particularly important. The ability to use raw THCa during work hours and activated product after work makes this product uniquely suited to our lifestyle.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis from fishing work, neuropathy from cold exposure)

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support during dark winter months

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN — the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN — above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress (isolation, seasonal affective disorder, PTSD)

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors. For Dillingham Census Area residents who may be new to cannabinoids, this conservative approach is especially important.

Delivery and global accessibility

OilWell operates the only RSO delivery system that reaches remote Alaska. We ship directly to Dillingham Census Area via USPS Priority Mail, typically 3-5 business days from our Houston facility to your location in Bristol Bay.

Alaska shipping details:

• Delivery method: USPS Priority Mail (3-5 business days)
• Packaging: Discreet, with no cannabis branding visible
• Documentation: Full COAs and receipts included for your records
• Tracking: Provided for all orders
• Temperature-stable packaging: Essential for Alaska’s variable climate
• Signature-required option: Available for added security

International shipping context: OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

All packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes. The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk. For Alaska residents, this is straightforward — hemp-derived products with less than 0.3% delta-9 THC are legal.

The significance of access cannot be overstated. Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Dillingham, a chronic pain patient in Togiak, or a veteran in New Stuyahok can now access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally — completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology — a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to patients in Dillingham Census Area searching for RSO.

How the OilWell formulas connect to the evidence

Every cannabinoid in OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene in OilWell’s formula — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell’s RSO guide makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context — the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. OilWell’s position — as stated by Colin Valencia in 2019 — is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand — it is a promise to its customers that it will always strive to deliver the best, most thoughtful cannabis products available. OilWell is not here to follow trends. It is here to set them. And as the company continues to grow, the focus remains on maintaining the same level of integrity, creativity, and commitment that has defined it from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia — Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving the fourth-largest city in the United States — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

For Dillingham Census Area residents ordering from a remote location, this media record provides third-party verification of our credibility. These are not paid advertisements — they are independently produced news segments from a major network affiliate that repeatedly identified Colin as the most credible voice in the industry.

Feature: Texas CBD businesses booming as industry continues to evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019

Colin’s quote from this feature captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Reporter: Tom Abrahams
Published: Monday, March 22, 2021

Colin’s therapy quote: “Pain comes in a lot of different forms.” This resonates across Dillingham Census Area, where pain from fishing, processing work, and arthritis affects so many.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Reporter: Steve Campion
Published: Monday, May 24, 2021

Colin’s iconic exchange: “Maybe you want to get high.” This unfiltered honesty demonstrates the transparency Dillingham Census Area residents can expect.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)
Published: Friday, August 20, 2021

OilWell gave away 1,000 caviar pre-rolls (approximately $35,000 in product) to encourage COVID vaccination, coordinated with the city of Houston. This community action demonstrates OilWell’s values.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021

Colin proactively removed all Delta-8 products before enforcement and warned other operators. This ethical leadership under pressure shows the character of the company Dillingham Census Area residents are supporting.

Feature: Biden marijuana pardon — experts weigh in on why Texas won’t see impact — October 7, 2022

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, October 7, 2022

This feature revealed Colin’s personal marijuana conviction history, adding weight to every quote about therapy and education. For Dillingham Census Area residents who have lived with the consequences of cannabis criminalization, this personal stake matters.

Feature: Marijuana industry getting creative as Texas laws continue to change — April 21, 2023

Source: ABC13 Houston (KTRK)
Reporter: Nick Natario
Published: Friday, April 21, 2023

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.” This forward-looking perspective positions OilWell at the frontier of the industry.

The through-line — what the media record reveals

Taken together, these seven ABC13 features and one YouTube clip tell a story that no single article could capture on its own.

Consistency across years. Colin Valencia appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Through every shift in Texas cannabis law, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics.

Community action. The COVID vaccine giveaway — $35,000 in product, coordination with city government, no political strings — is documented evidence of the community-first philosophy.

Personal stakes. The revelation that Colin has a personal marijuana conviction history transforms the entire media record. He is not an outside entrepreneur; he is someone who lived the consequences and built a legal business to prove the industry could operate with integrity.

Evolution of language. From “local wholesaler” in 2019 to industry authority by 2023, the media record tracks the growth of both the business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. For Dillingham Census Area residents ordering from a distance, this is third-party verification that cannot be purchased.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

For Dillingham Census Area residents researching their health options, understanding this hierarchy helps distinguish marketing hype from scientific reality.

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient [1]-[6].
• What is best supported: purified CBD has the most credible human evidence in seizure disorders [1][2].
• Anxiety research: a 2024 systematic review reported a statistically significant anxiolytic signal, but stressed limited clinical samples [3].
• Pain research: a 2024 systematic review concluded the pain literature is promising but heterogeneous [4].
• Sleep research: a 2023 insomnia review found the literature methodologically weak [5].
• Safety concerns: a 2023 systematic review found a real signal for liver enzyme elevation [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG appears pharmacologically distinct from both THC and CBD, interacting with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling [7].
• Potential areas: neurologic disorders, inflammatory bowel disease, antibacterial activity — primarily pharmacology-led hypotheses [7][8].
• Caution: CBG is sold commercially while the evidence base remains thin [7].

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: a 2022 review found delta-8 THC and delta-9 THC have broadly similar behavior, but delta-8 appears less potent due to weaker CB1 affinity [9].
• Public-health concerns: a 2023 scoping review noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing: commercial interest is tied to stability and easier synthesis relative to naturally scarce plant levels [11].
• Bottom line: treat delta-8 THC as a psychoactive THC analogue with incomplete human safety characterization [9]-[11].

THCa

• Evidence profile: important chemically, but low on direct human therapeutic evidence [12].
• What it is: THCa is the acidic precursor of THC. Decarboxylation converts THCa to THC during heating and storage [12].
• Psychoactivity: THCa itself does not produce psychoactive effects, but only if it stays in acidic form [12].
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not established human outcomes [12].

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids, but also clearest adverse-effect burden [1][13]-[15].
• Best supported: NCCIH identifies relevance to chemotherapy nausea, HIV/AIDS appetite, some MS and pain outcomes [1].
• Pain evidence: a 2022 systematic review found high-THC products may provide short-term pain benefit but increase dizziness, sedation, nausea, and discontinuation [13].
• Mental-health risk: a 2025 systematic review found consistent unfavorable associations with psychosis/schizophrenia and cannabis use disorder [15].

CBN

• Evidence profile: weak human evidence; marketing has moved ahead of data [12][16][17].
• Sleep claims: a 2021 review screened 99 human-study abstracts and found no clinical trials using validated sleep questionnaires [16].
• Broader literature: a 2024 sleep review concluded overall cannabinoid sleep research still lacks scale and quality [17].

CBC

• Evidence profile: emerging, intriguing, overwhelmingly preclinical [18][19].
• Pharmacology: 2024 review argues CBC has distinct pharmacodynamics and receptor behavior, highlighting antinociceptive, antibacterial, and anti-seizure areas [18].
• Safety: over-the-counter CBC products are sold despite little evidence establishing clinical efficacy or safety [18].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities [21].
• Safety: limonene oxidation products are clinically relevant contact allergens [22].

Myrcene

• Evidence profile: mostly preclinical, very limited human evidence [20][23].
• Research summary: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, but explicitly states human studies are lacking [23].
• Interpretation caution: claims that myrcene reliably causes sedation exceed current evidence [20][23].

Caryophyllene

• Evidence profile: most mechanistically interesting due to CB2 receptor agonism, but still preclinical [24].
• Why it stands out: 2021 review describes beta-caryophyllene as a selective CB2 receptor agonist [24].
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective [24].

Pinene

• Evidence profile: promising preclinical literature, weak human confirmation [20][25].
• Brain-health framing: 2021 review found antioxidant, anti-inflammatory, neuroprotective signals, but emphasized lack of well-designed clinical trials [25].

Linalool

• Evidence profile: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: discussed in relation to stress, mood, brain-health pharmacology [25][26].
• Safety: oxidized linalool hydroperoxides are recognized allergens [22].

Humulene

• Evidence profile: translationally interesting, but early [20][27].
• Scoping-review findings: 2024 review found broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties [27].

Terpinolene

• Evidence profile: least clinically characterized [20][28].
• Systematic-review findings: 2021 review concluded evidence base is dominated by in silico, in vitro, and animal studies rather than human trials [28].

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC support most detailed statements; others require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting because underexplored, but claims often become inflated.
• Product quality matters as much as molecule identity [1][10][11][14].
• THCa chemistry changes with storage and heating [12].

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: sleep evidence for CBN remains weak, with no strong validated-trial base [16][17].
• Overstatement: myrcene is a proven human sedative.
  More accurate: preclinical bioactivity is plausible, but direct human proof is limited [20][23].
• Overstatement: terpenes have proven entourage effects.
  More accurate: hypotheses are influential, but robust clinical proof remains limited [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating converts THCa to THC [12].
• Overstatement: delta-8 THC is safe because hemp-derived.
  More accurate: delta-8 THC is psychoactive with incomplete safety characterization [9]-[11].

Practical takeaways for the formulas in this document

• Most evidence-developed actives: CBD and delta-9 THC.
• Delta-8 THC is not trivial; it is psychoactive with less robust characterization.
• THCa meaningfully changes with processing.
• CBG, CBN, CBC are scientifically credible but clinically immature.
• Terpenes are relevant to aroma/flavor, but compound-specific therapeutic claims should be conservative.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Carrier: Organic MCT oil
• Price: $129.99
• Available for delivery throughout Dillingham Census Area

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• 510-thread compatibility: Universal battery compatible
• Price: $49.99
• Available for delivery throughout Dillingham Census Area

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene — citrus-bright, mood-elevating
• Myrcene — earthy, relaxing
• Caryophyllene (β-caryophyllene) — pepper/spice, CB2 agonist for inflammation
• Pinene — forest-fresh, clarity
• Linalool — floral/lavender, calming
• Humulene — earthy/woody, anti-inflammatory
• Terpinolene — piney/fruity, sparkling complexity

This terpene profile reflects Dillingham Census Area’s natural environment — the spruce forests, wild berries, and clean air of Bristol Bay. The aromas and flavors connect to our sensory experience of place.

How to Order for Dillingham Census Area:

1. Online: Visit oilwellcbd.com and select your products
2. Shipping: Enter your Dillingham Census Area address (Togiak, New Stuyahok, Dillingham, etc.)
3. Delivery: USPS Priority Mail (3-5 business days) with tracking
4. Questions: Call (832) 416-2816 or email [email protected]
5. COAs: Available on request, included with shipment

Age Requirement: 21+ only

Legal Compliance: Farm Bill compliant, hemp-derived, less than 0.3% delta-9 THC

Dillingham Census Area Residents: We understand your unique challenges — isolation, harsh weather, limited healthcare access, and the physical demands of subsistence and commercial fishing. Our multi-cannabinoid, patient-controlled approach is designed for your reality. Whether you’re dealing with chronic pain from years on a boat, PTSD from military service, sleep issues during the dark winters, or supporting a loved one through cancer treatment, we provide the education, transparency, and product quality you deserve.

This is not snake oil. This is not false hope. This is honest cannabinoid medicine, delivered to Bristol Bay.

---